We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Allergy Therapeutics Plc | LSE:AGY | London | Ordinary Share | GB00B02LCQ05 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.05 | 1.79% | 2.85 | 2.80 | 2.90 | 2.875 | 2.80 | 2.80 | 280,500 | 09:00:28 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 59.59M | -43.07M | -0.0090 | -3.17 | 135.84M |
Date | Subject | Author | Discuss |
---|---|---|---|
19/5/2014 07:55 | Opposite direction impo but seek and ye shall find, would keep you in here!!!!! | jimmyloser | |
19/5/2014 07:38 | a spiky spiky to 30p early morning? | bad robot | |
18/5/2014 07:43 | From the interims.... "Dosing completed in Pollinex Quattro Birch dose ranging study in Germany" Worth doing a little Googling!!! (now that's a new word). DYOR. and you may find much more like this "These results support the further use of monophosphoryl lipid A (MPL®) adjuvant in allergen IT" Seek and Ye shall find ! | jimmyloser | |
17/5/2014 18:59 | We have seen it all before - the overhang cleared and a few chancers jump on board. | jimmyloser | |
17/5/2014 16:41 | Very quiet considering the 7p rise. | chicken charlie | |
17/5/2014 09:48 | We need those earnings figs to grow in order to bring the PE ratio down - currently 121 according to the Key numbers in the ThisisMoney summary. FG | farmer george | |
17/5/2014 08:10 | General interest | jimmyloser | |
16/5/2014 19:41 | Just seen the rise, WOW!! what's going on then? Been watching the golf most of the afternoon..:0)))) AuDigger: Lol...:0)) | cube boss | |
16/5/2014 18:06 | Apparently Cubes dog was attacked by a very defensive cat! | audigger | |
16/5/2014 17:31 | jimmyloser - lol. And here's me thinking the dog had run off. Was thinking of buying him one myself. FG | farmer george | |
16/5/2014 17:21 | Cube: You have a nice surprise waiting when you get back from your walk... Await your comments with great interest. | lordshaw | |
16/5/2014 17:09 | Paul Erlich Institure -Cube will throw more light on it - I hear he took his new dog for a walk at 2pm and isn't back yet. See RNS's | jimmyloser | |
16/5/2014 17:05 | jimmyloser - PEI? FG | farmer george | |
16/5/2014 16:59 | What a ride - wonder what's behind it? FG | farmer george | |
16/5/2014 16:58 | I wouldn't bank on it guys. As I posted earlier we have had a big buyer (along with myself) buying in here for the last week or two on the back of panicky sellers and the IC saying to 'traders' take your profits. 'Investors' have sat tight. To-day the big guns decided to play and mop up the low hanging fruit. The price now seems right to me until news. PEI? Director Buying? An approach? A USA partner? -wow I don't expect any excitement on this level until a RNS IMPO/DYOR Ecstatic to be proved wrong though. | jimmyloser | |
16/5/2014 16:53 | How lucky, I had a work commitment today and was going to sell @ 15p, as I too was getting fed up waiting for any news to come, what a surprise to get back and see an offer @ 24p. and going forward what price Monday then? | 1goodman | |
16/5/2014 16:50 | So good I said it twice! | aruntim | |
16/5/2014 16:43 | Forget 30p guys, hope it's not too late for the weekend papers! | aruntim | |
16/5/2014 16:43 | Forget 30p guys, hope it's not too late for the weekend papers! | aruntim | |
16/5/2014 16:28 | Look likes monday morning buying stampede to 30p | bad robot | |
16/5/2014 16:26 | Back-in at 22.5. Bad timing I admit but as I said before, I believe the story but I really expected it to go lower. | audigger | |
16/5/2014 16:20 | 14p doom merchant here! Must be news afoot! | audigger | |
16/5/2014 16:17 | These pending changes to that market's dynamics, along with our own progress made with the North American regulatory authorities, underscores our confidence that the US market will emerge as a valuable market for registered allergy vaccines. We continue to explore our strategic options for the development and commercialisation of Pollinex Quattro in these territories where we see a "compelling opportunity to be first to market" in the subcutaneous segment with short-course products that could revolutionise the way such immunotherapy treatments are administered. | jimmyloser |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions